News for 'Divyaxa Agnihotri of HDFC Securities'

Sun Pharma's Organon deal: Strategic entry into new segments, but integration challenges loom

Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.